Mysscat,
The following from the July 12, 2005 SEC Form 10KSB/A should help:
ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
As of December 31, 2000, Biocurex was engaged in the acquisition and sale of thoroughbred racing horses. As of December 31, 2000 Biocurex owned one thoroughbred horse and had 2,525,000 outstanding shares of common stock. The officers and directors of Biocurex at that time were Kevin B. Halter, Kevin B. Halter Jr., and Pam J. Halter. The Halter's collectively owned 1,900,000 shares of Biocurex's common stock. During the year ended December 31, 2001, Biocurex transferred the thoroughbred horse, having a net book value of $13,128, to the Halter's as payment in full on the advances given to Biocurex totaling $72,303. The difference of $59,175 was recorded as a contribution to capital.
On February 20, 2001, Ignacio Martinelli purchased 1,892,308 shares from the Halters for $50,000. In connection with this transaction, the Halters elected Mr. Martinelli as a director and then resigned their positions as officers and directors of Biocurex. Biocurex also ceased its business activities relating to the acquisition and sale of thoroughbred racehorses.
On February 21, 2001, Biocurex issued 150,000 (1,950,000 post split) shares of its common stock to acquire all of the issued and outstanding shares of Lagostar Trading S.A. At the time of this acquisition, Lagostar Trading owned certain technology and patents, which relate to the early detection of cancer. Prior to its acquisition by Biocurex, all of the outstanding shares of Lagostar Trading were owned by relatives of Dr. Ricardo Moro, an officer and director of Biocurex.
On March 1, 2001, Biocurex's Board of Directors declared a 13-for-1 forward stock split.
As a result of this forward split, Mr. Martinelli owned 24,600,004 shares of common stock and Biocurex's capitalization increased to 32,825,026 outstanding shares of common stock.
kag
News 
Market Data 
Discover 
